A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This Phase 1, open-label, single dose study is designed to evaluate the pharmacokinetics,
safety and tolerability of a single 1.5 mg tivozanib dose in subjects with varying degrees of
hepatic impairment and normal hepatic function.